In order to mitigate T cell death and enhance anti-tumor activity, T cells transferred into patients may be supported with exogenous IL-2, but off-target activation of self-directed CD8+ T-cells and regulatory CD4+ T-cells limit the efficacy of IL-2 and there is a recognized need for alternative methods to support cells in vivo [21]. The gene discussed is CD8A; the disease is neoplasm.